© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 14, 1040-1043,
July 16, 2003
© 2003 Oxford University Press
COMMENTARY |
Is Positron Emission Tomography an Accurate Non-invasive Alternative to Sentinel Lymph Node Biopsy in Breast Cancer Patients?
Affiliations of authors: U. Guller, Dept. of Surgery, University of Basel, Basel, Switzerland and Department of Surgery, Duke University Medical Center, Durham, NC; E. Nitzsche, Department of Radiology, Institute of Nuclear Medicine, University of Basel, Basel, Switzerland; H. Moch, Institute of Pathology, University of Basel, Basel, Switzerland; M. Zuber, Department of Surgery, Kantonsspital Olten, Olten, Switzerland.
Correspondence to: Markus Zuber, M.D., Dept. of Surgery, Kantonsspital Olten, CH-4600 Olten, Switzerland (e-mail: mzuber_ol@spital.ktso.ch).
| The first 150 words of the full text of this article appear below. |
Breast cancer is the most common malignancy among women, leading to approximately 45 000 deaths per annum in the United States (1). The presence of axillary lymph node metastases has major prognostic implications in breast cancer patients (2,3), and it is an important criterion in determining the need for adjuvant chemotherapy (4). Sentinel lymph node (SLN) biopsy has become routine practice in the surgical treatment of patients with breast cancer because the disease status of the SLNs accurately reflects the status of the remaining axillary lymph nodes (57). Hence, patients who present with a negative SLN (no metastases) can be spared from having a more traumatic axillary lymph node dissection (ALND), which has been shown to be associated with substantial short- and long-term sequelae (8,9). Despite the enormous advantages of SLN biopsy over ALND
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. C. Hodgson and K. Y. Gulenchyn Is There a Role for Positron Emission Tomography in Breast Cancer Staging? J. Clin. Oncol., February 10, 2008; 26(5): 712 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
U Veronesi, C De Cicco, V. Galimberti, J. Fernandez, N Rotmensz, G Viale, G Spano, A Luini, M Intra, P Veronesi, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases Ann. Onc., March 1, 2007; 18(3): 473 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Quon and S. S. Gambhir FDG-PET and Beyond: Molecular Breast Cancer Imaging J. Clin. Oncol., March 10, 2005; 23(8): 1664 - 1673. [Full Text] [PDF] |
||||
![]() |
F. A. Jaffer and R. Weissleder Molecular Imaging in the Clinical Arena JAMA, February 16, 2005; 293(7): 855 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann Lymphatic Drainage Imaging of Breast Cancer in Mice by Micro-Magnetic Resonance Lymphangiography Using a Nano-Size Paramagnetic Contrast Agent J Natl Cancer Inst, May 5, 2004; 96(9): 703 - 708. [Abstract] [Full Text] [PDF] |
||||



